Remove Licensing Remove Marketing Remove Pharma Companies Remove Sales
article thumbnail

World’s Top 10 Pharma Companies (By 2023 Revenue)

XTalks

The global pharmaceutical market has been expanding at an unprecedented pace. According to Statista , in 2023, the market was estimated to be worth about $1.6 The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 billion last year, up 4.2

article thumbnail

Ipsen plans sale of consumer health business for €350m

pharmaphorum

Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. The post Ipsen plans sale of consumer health business for €350m appeared first on. billion of its revenues last year.

Sales 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

To insource or outsource drug commercialisation? Flexibility is the answer

Pharmaceutical Technology

In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. One interesting trend is the number of small cap companies and first-time launchers commencing this journey. The rate of drug approvals could be on the rise.

Drugs 130
article thumbnail

Dr Reddy’s jumps on medical cannabis train, buying Nimbus Health

pharmaphorum

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum.

Licensing 119
article thumbnail

Bayer sells testosterone drug rights to Grünenthal for €500m

pharmaphorum

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year. Grünenthal will make the purchase in cash upfront, with the final figure dependent on any closing adjustments.

Drugs 95
article thumbnail

The post-COVID future of physician sample access and engagement

pharmaphorum

For the pharma industry, the pandemic’s changes were both abrupt and industry-altering, requiring companies to rapidly adapt their approaches to drug development and commercialisation. It also led to changes in how we manufacturer, market and ship medications. Personalisation is Key. Redefining Success Metrics.

Sales 98
article thumbnail

Breaking into the global pharmaceutical market

pharmaphorum

RudaCure is a four-year-old biotech company based in the South Korea, focusing on ocular disease and chronic pain with a pair of potentially first-in-class drugs. The company recently raised $16.5 So] we are trying to go for the international market.”. “In The company’s second drug candidate, RCI002, is focused on chronic pain.